Friday, 26 April 2024
Aimmune Therapeutics Inc.
No Risk Alert Here: Before we dive into any analysis we simply note that Aimmune Therapeutics Inc (NASDAQ:AIMT) risk is neither elevated nor depressed.
more»
The results here are provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation.
more»
01:56 | 13/3/18
Market Exclusive
On March 12, 2018, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2017, and its financial position as of December 31, 2017.
more»
01:11 | 13/3/18
Albany Times Union
BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Monday reported a loss of $41.2 million in its fourth quarter. On a per-share basis, the Brisbane, California-based company said it had a loss of 81 cents.
more»
01:00 | 13/3/18
Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2017.
more»
01:56 | 8/3/18
Business Wire
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies.
more»
07:56 | 5/3/18
Business Wire
BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its pivotal Phase 3 PALISADE ...
more»
21:37 | 4/3/18
Seeking Alpha
Aimmune Therapeutics, Inc. (AIMT) is a Brisbane, California based clinical stage biopharma concern engaged in the development of treatments for food allergies.
more»
01:00 | 28/2/18
Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the evening of March ...
more»
In trading on Monday, shares of Aimmune Therapeutics Inc (Symbol: AIMT) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $29.815 per share.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |